Form 4: Vir Biotechnology SVP Brent Sabatini Reports Sale of Shares to Cover Tax Obligations

Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 1,562 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On February 13, 2025, Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 1,562 shares of common stock.
• The sale was executed at a price of $9.1494 per share.
• This transaction was conducted to cover the issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
• Following the transaction, Sabatini beneficially owns 28,189 shares of Vir Biotechnology common stock, which includes 1,312 shares acquired on November 29, 2024, through the employee stock purchase program.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects a routine transaction to cover tax obligations, with no indication of positive or negative implications for the company's performance.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates a sale of shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by an officer may have a minor impact on shareholders, but is unlikely to be significant as it is a routine transaction.

Key Dates

Keywords

Form 4, Vir Biotechnology, Brent Sabatini, Stock Sale, Tax Withholding, Beneficial Ownership, SVP, Chief Accounting Officer